Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans

Drug Metabolism and Pharmacokinetics

Volumn 33, Issue 1, 2018, Pages 9-16

  Fujiwara, Ryoichi ^a   Yoda, Emiko ^b   Tukey, Robert H ^c  

^a KITASATO UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug metabolism; Glucuronidation; Humanized mice; Species difference; Toxicity; UDP glucuronosyltransferase

Indexed keywords

GLUCURONOSYLTRANSFERASE; ISOTHIOCYANIC ACID DERIVATIVE; UDP GLUCURONOSYLTRANSFERASE MICE; UNCLASSIFIED DRUG; GLUCURONIDE; UGT1A1 ENZYME;

DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG TOXICITY; GENE INDUCTION; HUMAN; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SPECIES DIFFERENCE; ADVERSE DRUG REACTION; ANIMAL; DRUG EFFECT; ENZYMOLOGY; FORECASTING; GENETICS; LIVER MICROSOME; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FORECASTING; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; METABOLIC CLEARANCE RATE; MICE; MICE, TRANSGENIC; MICROSOMES, LIVER; SPECIES SPECIFICITY;

EID: 85032205896     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.1016/j.dmpk.2017.10.002     Document Type: Review

References (104)

1. Dutton, G.J., Acceptor substrates of UDP glucuronosyltransferase and their assay. Dutton, G.J., (eds.) Glucuronidation of drugs and other compounds, 1980, CRC Press, Boca Raton, FL, 69–78.
2. Williams, J.A., Hyland, R., Jones, B.C., Smith, D.A., Hurst, S., Goosen, T.C., et al. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos 32 (2004), 1201–1208.
3. Mackenzie, P.I., Walter Bock, K., Burchell, B., Guillemette, C., Ikushiro, S., Iyanagi, T., et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15 (2005), 677–685.
4. Mackenzie, P.I., Rogers, A., Treloar, J., Jorgensen, B.R., Miners, J.O., Meech, R., Identification of UDP glycosyltransferase 3A1 as a UDP N-acetylglucosaminyltransferase. J Biol Chem 283 (2008), 36205–36210.
5. Liu, Y., Ramírez, J., House, L., Ratain, M.J., Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos 38 (2010), 32–39.
6. Kuypers, D.R., Verleden, G., Naesens, M., Vanrenterghem, Y., Drug interaction between mycophenolate mofetil and rifampin: possible induction of uridine diphosphate-glucuronosyltransferase. Clin Pharmacol Ther 78 (2005), 81–88.
7. Ando, Y., Saka, H., Asai, G., Sugiura, S., Shimokata, K., Kamataki, T., UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 9 (1998), 845–847.
8. Shipkova, M., Armstrong, V.W., Oellerich, M., Wieland, E., Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther Drug Monit 25 (2003), 1–16.
9. Mitsugi, R., Sumida, K., Fujie, Y., Tukey, R.H., Itoh, T., Fujiwara, R., Acyl-glucuronide as a possible cause of trovafloxacin-induced liver toxicity: induction of chemokine (C-X-C motif) ligand 2 by trovafloxacin acyl-glucuronide. Biol Pharm Bull 39 (2016), 1604–1610.
10. Yamanaka, H., Nakajima, M., Katoh, M., Yokoi, T., Glucuronidation of thyroxine in human liver, jejunum, and kidney microsomes. Drug Metab Dispos 35 (2007), 1642–1648.
11. Hirashima, R., Michimae, H., Takemoto, H., Sasaki, A., Kobayashi, Y., Itoh, T., et al. Induction of the UDP-glucuronosyltransferase 1A1 during the perinatal period can cause neurodevelopmental toxicity. Mol Pharmacol 90 (2016), 265–274.
12. Katoh, M., Matsui, T., Yokoi, T., Glucuronidation of antiallergic drug, tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos 35 (2007), 583–589.
13. Fujiwara, R., Sumida, K., Kutsuno, Y., Sakamoto, M., Itoh, T., UDP-glucuronosyltransferase (UGT) 1A1 mainly contributes to the glucuronidation of trovafloxacin. Drug Metab Pharmacokinet 30 (2015), 82–88.
14. Troberg, J., Järvinen, E., Ge, G.B., Yang, L., Finel, M., UGT1A10 is a high activity and important extrahepatic enzyme: why has its role in intestinal glucuronidation been frequently underestimated?. Mol Pharm 14 (2017), 2875–2883.
15. Nakajima, M., Koga, T., Sakai, H., Yamanaka, H., Fujiwara, R., Yokoi, T., N-Glycosylation plays a role in protein folding of human UGT1A9. Biochem Pharmacol 79 (2010), 1165–1172.
16. Fujiwara, R., Nakajima, M., Yamanaka, H., Nakamura, A., Katoh, M., Ikushiro, S., et al. Effects of coexpression of UGT1A9 on enzymatic activities of human UGT1A isoforms. Drug Metab Dispos 35 (2007), 747–757.
17. Nakajima, M., Yamanaka, H., Fujiwara, R., Katoh, M., Yokoi, T., Stereoselective glucuronidation of 5-(4'-hydroxyphenyl)-5-phenylhydantoin by human UDP-glucuronosyltransferase (UGT) 1A1, UGT1A9, and UGT2B15: effects of UGT-UGT interactions. Drug Metab Dispos 35 (2007), 1679–1686.
18. Fujiwara, R., Nakajima, M., Oda, S., Yamanaka, H., Ikushiro, S., Sakaki, T., et al. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J Pharm Sci 99 (2010), 442–454.
19. Fujiwara, R., Itoh, T., Extensive protein-protein interactions involving UDP-glucuronosyltransferase (UGT) 2B7 in human liver microsomes. Drug Metab Pharmacokinet 29 (2014), 259–265.
20. Fujiwara, R., Itoh, T., Extensive protein interactions involving cytochrome P450 3A4: a possible contributor to the formation of a metabolosome. Pharmacol Res Perspect, 2, 2014, e00053.
21. Lin, J.H., Wong, B.K., Complexities of glucuronidation affecting in vitro in vivo extrapolation. Curr Drug Metab 3 (2002), 623–646.
22. Soars, M.G., Burchell, B., Riley, R.J., In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J Pharmacol Exp Ther 301 (2002), 382–390.
23. Deguchi, T., Watanabe, N., Kurihara, A., Igeta, K., Ikenaga, H., Fusegawa, K., et al. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach. Drug Metab Dispos 39 (2011), 820–829.
24. Martignoni, M., Groothuis, G.M., de Kanter, R., Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2 (2006), 875–894.
25. Miles, K.K., Stern, S.T., Smith, P.C., Kessler, F.K., Ali, S., Ritter, J.K., An investigation of human and rat liver microsomal mycophenolic acid glucuronidation: evidence for a principal role of UGT1A enzymes and species differences in UGT1A specificity. Drug Metab Dispos 33 (2005), 1513–1520.
26. Shiratani, H., Katoh, M., Nakajima, M., Yokoi, T., Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36 (2008), 1745–1752.
27. Katoh, M., Tateno, C., Yoshizato, K., Yokoi, T., Chimeric mice with humanized liver. Toxicology 246 (2008), 9–17.
28. Fujiwara, R., Maruo, Y., Chen, S., Tukey, R.H., Role of extrahepatic UDP-glucuronosyltransferase 1A1: advances in understanding breast milk-induced neonatal hyperbilirubinemia. Toxicol Appl Pharmacol 289 (2015), 124–132.
29. Tukey, R.H., Strassburg, C.P., Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40 (2000), 581–616.
30. Fisher, M.B., Paine, M.F., Strelevitz, T.J., Wrighton, S.A., The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33 (2001), 273–297.
31. Cheung, C., Gonzalez, F.J., Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327 (2008), 288–299.
32. Chen, S., Beaton, D., Nguyen, N., Senekeo-Effenberger, K., Brace-Sinnokrak, E., Argikar, U., et al. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280 (2005), 37547–37557.
33. Nguyen, N., Bonzo, J.A., Chen, S., Chouinard, S., Kelner, M.J., Hardiman, G., et al. Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem 283 (2008), 7901–7911.
34. Fujiwara, R., Nguyen, N., Chen, S., Tukey, R.H., Developmental hyperbilirubinemia and CNS toxicity in mice humanized with the UDP glucuronosyltransferase 1 (UGT1) locus. Proc Natl Acad Sci U S A 107 (2010), 5024–5029.
35. Ritter, J.K., Chen, F., Sheen, Y.Y., Tran, H.M., Kimura, S., Yeatman, M.T., et al. A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J Biol Chem 267 (1992), 3257–3261.
36. Nakamura, A., Nakajima, M., Yamanaka, H., Fujiwara, R., Yokoi, T., Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36 (2008), 1461–1464.
37. Iyer, L., King, C.D., Whitington, P.F., Green, M.D., Roy, S.K., Tephly, T.R., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101 (1998), 847–854.
38. Green, M.D., King, C.D., Mojarrabi, B., Mackenzie, P.I., Tephly, T.R., Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26 (1998), 507–512.
39. Nakajima, M., Tanaka, E., Kobayashi, T., Ohashi, N., Kume, T., Yokoi, T., Imipramine N-glucuronidation in human liver microsomes: biphasic kinetics and characterization of UDP-glucuronosyltransferase isoforms. Drug Metab Dispos 30 (2002), 636–642.
40. Mizuma, T., Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Int J Pharm 378 (2009), 140–141.
41. Oda, S., Fujiwara, R., Kutsuno, Y., Fukami, T., Itoh, T., Yokoi, T., et al. Targeted screen for human UDP-glucuronosyltransferases inhibitors and the evaluation of potential drug-drug interactions with zafirlukast. Drug Metab Dispos 43 (2015), 812–818.
42. Green, M.D., Tephly, T.R., Glucuronidation of amine substrates by purified and expressed UDP-glucuronosyltransferase proteins. Drug Metab Dispos 26 (1998), 860–867.
43. Buckley, D.B., Klaassen, C.D., Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35 (2007), 121–127.
44. Kutsuno, Y., Sumida, K., Itoh, T., Tukey, R.H., Fujiwara, R., Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: similarity with glucuronidation in human liver microsomes. Pharmacol Res Perspect, 1, 2013, e00002.
45. Kutsuno, Y., Itoh, T., Tukey, R.H., Fujiwara, R., Glucuronidation of drugs and drug-induced toxicity in humanized UDP-glucuronosyltransferase 1 mice. Drug Metab Dispos 42 (2014), 1146–1152.
46. Bosma, P.J., Seppen, J., Goldhoorn, B., Bakker, C., Oude Elferink, R.P., Chowdhury, J.R., et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 269 (1994), 17960–17964.
47. Choksi, N.Y., Jahnke, G.D., St Hilaire, C., Shelby, M., Role of thyroid hormones in human and laboratory animal reproductive health. Birth Defects Res B Dev Reprod Toxicol 68 (2003), 479–491.
48. Cai, H., Nguyen, N., Peterkin, V., Yang, Y.S., Hotz, K., La Placa, D.B., et al. A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation. Drug Metab Dispos 38 (2010), 879–886.
49. Kutsuno, Y., Hirashima, R., Sakamoto, M., Ushikubo, H., Michimae, H., Itoh, T., et al. Expression of UDP-glucuronosyltransferase 1 (UGT1) and glucuronidation activity toward endogenous substances in humanized UGT1 mouse brain. Drug Metab Dispos 43 (2015), 1071–1076.
50. Mackenzie, P.I., Gregory, P.A., Gardner-Stephen, D.A., Lewinsky, R.H., Jorgensen, B.R., Nishiyama, T., et al. Regulation of UDP glucuronosyltransferase genes. Curr Drug Metab 4 (2003), 249–257.
51. Sugatani, J., Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. Drug Metab Pharmacokinet 28 (2013), 83–92.
52. Shibuya, A., Itoh, T., Tukey, R.H., Fujiwara, R., Impact of fatty acids on human UDP-glucuronosyltransferase 1A1 activity and its expression in neonatal hyperbilirubinemia. Sci Rep, 3, 2013, 2903.
53. Fujiwara, R., Chen, S., Karin, M., Tukey, R.H., Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia. Gastroenterology 142 (2012), 109–118.
54. Sumida, K., Kawana, M., Kouno, E., Itoh, T., Takano, S., Narawa, T., et al. Importance of UDP-glucuronosyltransferase 1A1 expression in skin and its induction by UVB in neonatal hyperbilirubinemia. Mol Pharmacol 84 (2013), 679–686.
55. Sakamoto, M., Itoh, T., Tukey, R.H., Fujiwara, R., Nicotine regulates the expression of UDP-glucuronosyltransferase (UGT) in humanized UGT1 mouse brain. Drug Metab Pharmacokinet 30 (2015), 269–275.
56. Chen, S., Yueh, M.F., Evans, R.M., Tukey, R.H., Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice. Hepatology 56 (2012), 658–667.
57. Maglich, J.M., Parks, D.J., Moore, L.B., Collins, J.L., Goodwin, B., Billin, A.N., et al. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem 278 (2003), 17277–17283.
58. Moore, L.B., Parks, D.J., Jones, S.A., Bledsoe, R.K., Consler, T.G., Stimmel, J.B., et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem 275 (2000), 15122–15127.
59. Tzameli, I., Pissios, P., Schuetz, E.G., Moore, D.D., The xenobiotic compound 1,4-bis[2-(3,5-dichloropyridyloxy)]benzene is an agonist ligand for the nuclear receptor CAR. Mol Cell Biol 20 (2000), 2951–2958.
60. Lehmann, J.M., McKee, D.D., Watson, M.A., Willson, T.M., Moore, J.T., Kliewer, S.A., The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102 (1998), 1016–1023.
61. Aoshima, N., Fujie, Y., Itoh, T., Tukey, R.H., Fujiwara, R., Glucose induces intestinal human UDP-glucuronosyltransferase (UGT) 1A1 to prevent neonatal hyperbilirubinemia. Sci Rep, 4, 2014, 6343.
62. Rubenstein, J.H., Laine, L., Systematic review: the hepatotoxicity of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20 (2004), 373–380.
63. Lapeyre-Mestre, M., de Castro, A.M.R., Bareille, M.P., Del Pozo, J.G., Requejo, A.A., Arias, L.M., et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 20 (2006), 391–395.
64. Calvo, R., Obregón, M.J., De Ona, C.R., Del Rey, F.E., De Escobar, G.M., Congenital hypothyroidism, as studied in rats. Crucial role of maternal thyroxine but not of 3, 5, 3'-triiodothyronine in the protection of the fetal brain. J Clin Invest, 86, 1990, 889.
65. Koibuchi, N., Chin, W.W., Thyroid hormone action and brain development. Trends Endocrinol Metab 11 (2000), 123–128.
66. Koopman-Esseboom, C., Morse, D.C., Weisglas-Kuperus, N., Lutkeschipholt, I.J., Van der Paauw, C.G., Tuinstra, L.G., et al. Effects of dioxins and polychlorinated biphenyls on thyroid hormone status of pregnant women and their infants. Pediatr Res 36 (1994), 468–473.
67. Franklyn, J.A., Sheppard, M.C., Ramsden, D.B., Measurement of free thyroid hormones in patients on long-term phenytoin therapy. Eur J Clin Pharmacol 26 (1984), 633–634.
68. Vanoverloop, D., Schnell, R.R., Harvey, E.A., Holmes, L.B., The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 14 (1992), 329–335.
69. Hurley, P.M., Mode of carcinogenic action of pesticides inducing thyroid follicular cell tumors in rodents. Environ Health Perspect 106 (1998), 437–445.
70. Doll, R., The lessons of life: keynote address to the nutrition and cancer conference. Cancer Res 52 (1992), 2024s–2029s.
71. de Verdier, M.G., Hagman, U., Peters, R.K., Steineck, G., Övervik, E., Meat, cooking methods and colorectal cancer: a case-referent study in Stockholm. Int J Cancer 49 (1991), 520–525.
72. Felton, J.S., Knize, M.G., Shen, N.H., Andresen, B.D., Bjeldanes, L.F., Hatch, F.T., Identification of the mutagens in cooked beef. Environ Health Perspect 67 (1986), 17–24.
73. Gooderham, N.J., Murray, S., Lynch, A.M., Yadollahi-Farsani, M., Zhao, K., Boobis, A.R., et al. Food-derived heterocyclic amine mutagens: variable metabolism and significance to humans. Drug Metab Dispos 29 (2001), 529–534.
74. Wakabayashi, K., Nagao, M., Esumi, H., Sugimura, T., Food-derived mutagens and carcinogens. Cancer Res 52 (1992), 2092s–2098s.
75. Layton, D.W., Bogen, K.T., Knize, M.G., Hatch, F.T., Johnson, V.M., Felton, J.S., Cancer risk of heterocyclic amines in cooked foods: an analysis and implications for research. Carcinogenesis 16 (1995), 39–52.
76. Ito, N., Hasegawa, R., Sano, M., Tamano, S., Esumi, H., Takayama, S., et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo [4, 5-b] pyridine (PhIP). Carcinogenesis 12 (1991), 1503–1506.
77. Sugimura, T., Nutrition and dietary carcinogens. Carcinogenesis 21 (2000), 387–395.
78. Thompson, L.H., Tucker, J.D., Stewart, S.A., Christensen, M.L., Salazar, E.P., Carrano, A.V., et al. Genotoxicity of compounds from cooked beef in repair-deficient CHO cells versus Salmonella mutagenicity. Mutagenesis 2 (1987), 483–487.
79. Sinha, R., Rothman, N., Brown, E.D., Salmon, C.P., Knize, M.G., Swanson, C.A., et al. High concentrations of the carcinogen 2-amino-1-methyl-6-phenylimidazo- [4,5-b]pyridine (PhIP) occur in chicken but are dependent on the cooking method. Cancer Res 55 (1995), 4516–4519.
80. Dingley, K.H., Curtis, K.D., Nowell, S., Felton, J.S., Lang, N.P., Turteltaub, K.W., DNA and protein adduct formation in the colon and blood of humans after exposure to a dietary-relevant dose of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Epidemiol Biomarkers Prev 8 (1999), 507–512.
81. Zheng, W., Gustafson, D.R., Sinha, R., Cerhan, J.R., Moore, D., Hong, C.P., et al. Well-done meat intake and the risk of breast cancer. J Natl Cancer Inst 90 (1998), 1724–1729.
82. Fujiwara, R., Nakajima, M., Yamanaka, H., Katoh, M., Yokoi, T., Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35 (2007), 1781–1787.
83. Malfatti, M.A., Felton, J.S., N-glucuronidation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and N_hydroxy-PhIP by specific human UDP-glucuronosyltransferases. Carcinogenesis 22 (2001), 1087–1093.
84. Malfatti, M.A., Kulp, K.S., Knize, M.G., Davis, C., Massengill, J.P., Williams, S., et al. The identification of [2-(14)C]2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine metabolites in humans. Carcinogenesis 20 (1999), 705–713.
85. Knize, M.G., Kulp, K.S., Salmon, C.P., Keating, G.A., Felton, J.S., Factors affecting human heterocyclic amine intake and the metabolism of PhIP. Mutat Res 506–7 (2002), 153–162.
86. Shapiro, T.A., Fahey, J.W., Dinkova-Kostova, A.T., Holtzclaw, W.D., Stephenson, K.K., Wade, K.L., et al. Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer 55 (2006), 53–62.
87. Shapiro, T.A., Fahey, J.W., Wade, K.L., Stephenson, K.K., Talalay, P., Chemoprotective glucosinolates and isothiocyanates of broccoli sprouts: metabolism and excretion in humans. Cancer Epidemiol Biomarkers Prev 10 (2001), 501–508.
88. Keum, Y.S., Jeong, W.S., Kong, A.N., Chemopreventive functions of isothiocyanates. Drug News Perspect 18 (2005), 445–451.
89. Saw, C.L., Cintrón, M., Wu, T.Y., Guo, Y., Huang, Y., Jeong, W.S., et al. Pharmacodynamics of dietary phytochemical indoles I3C and DIM: induction of Nrf2-mediated phase II drug metabolizing and antioxidant genes and synergism with isothiocyanates. Biopharm Drug Dispos 32 (2011), 289–300.
90. Hu, R., Xu, C., Shen, G., Jain, M.R., Khor, T.O., Gopalkrishnan, A., et al. Identification of Nrf2-regulated genes induced by chemopreventive isothiocyanate PEITC by oligonucleotide microarray. Life Sci 79 (2006), 1944–1955.
91. Yoda, E., Paszek, M., Konopnicki, C., Fujiwara, R., Chen, S., Tukey, R.H., Isothiocyanates induce UGT1A1 in humanized UGT1 mice in a CAR dependent fashion that is highly dependent upon oxidative stress. Sci Rep, 7, 2017, 46489.
92. Hoensch, H.P., Roelofs, H.M., Edler, L., Kirch, W., Peters, W.H., Disparities of conjugating protective enzyme activities in the colon of patients with adenomas and carcinomas. World J Gastroenterol 19 (2013), 6020–6025.
93. Giuliani, L., Ciotti, M., Stoppacciaro, A., Pasquini, A., Silvestri, I., De Matteis, A., et al. UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry. Oncol Rep 13 (2005), 185–191.
94. Chen, S., Yueh, M.F., Bigo, C., Barbier, O., Wang, K., Karin, M., et al. Intestinal glucuronidation protects against chemotherapy-induced toxicity by irinotecan (CPT-11). Proc Natl Acad Sci U S A 110 (2013), 19143–19148.
95. Strassburg, C.P., Manns, M.P., Tukey, R.H., Differential down-regulation of the UDP-glucuronosyltransferase 1A locus is an early event in human liver and biliary cancer. Cancer Res 57 (1997), 2979–2985.
96. Starlard-Davenport, A., Lyn-Cook, B., Radominska-Pandya, A., Identification of UDP-glucuronosyltransferase 1A10 in non-malignant and malignant human breast tissues. Steroids 73 (2008), 611–620.
97. Izumi, K., Li, Y., Ishiguro, H., Zheng, Y., Yao, J.L., Netto, G.J., et al. Expression of UDP-glucuronosyltransferase 1A in bladder cancer: association with prognosis and regulation by estrogen. Mol Carcinog 53 (2014), 314–324.
98. Wang, M., Qi, Y.Y., Chen, S., Sun, D.F., Wang, S., Chen, J., et al. Expression of UDP-glucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue. Oncol Lett 4 (2012), 925–930.
99. Liu, M., Chen, S., Yueh, M.F., Wang, G., Hao, H., Tukey, R.H., Reduction of p53 by knockdown of the UGT1 locus in colon epithelial cells causes an increase in tumorigenesis. Cell Mol Gastroenterol Hepatol 2 (2016), 63–76.
100. van Herwaarden, A.E., Wagenaar, E., van der Kruijssen, C.M., van Waterschoot, R.A., Smit, J.W., Song, J.Y., et al. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest 117 (2007), 3583–3592.
101. Fay, M.J., Nguyen, M.T., Snouwaert, J.N., Dye, R., Grant, D.J., Bodnar, W.M., et al. Xenobiotic metabolism in mice lacking the UDP-glucuronosyltransferase 2 family. Drug Metab Dispos 43 (2015), 1838–1846.
102. Fujiwara, R., Mitsugi, R., Uemura, A., Itoh, T., Tukey, R.H., Severe neonatal hyperbilirubinemia in Crigler-Najjar syndrome model mice can be reversed with zinc protoporphyrin. Hep Comm 1 (2017), 792–802.
103. Owens, I.S., Basu, N.K., Banerjee, R., UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 400 (2005), 1–22.
104. Bock, K.W., Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem Pharmacol 66 (2003), 691–696.